PIK3CA and colorectal carcinoma: Because NVP-BEZ235 inhibits the wild-type and mutant forms of PIK3CA with comparable efficacy [32], we hypothesized that NVP-BEZ235 may have significant efficacy in the treatment of PIK3CA wild-type CRC.